IV Dexmedetomidine as Spinal Anesthesia Adjuvant in Infants : RACHI_dex

University Hospital, Montpellier1 site in 1 country210 target enrollmentOctober 1, 2020

Overview

Spinal anesthesia in newborns is one of " Gold standard " techniques in short subumbilical surgeries (less than 30 minutes) with advantage of avoiding the risks inherent to general anesthesia.
Spinal anesthesia of the newborn remains a complex technical procedure with a failure rate of up to 16%. The child's movements and certain degrees of discomfort may also interfere with the successful completion of the procedure.
The second major issue of spinal anesthesia is the limitation of the motor block duration and the need for general anesthesia to complete the surgery
Spinal anesthesia duration can be prolonged by the addition of differents adjuvant such as opioid or alpha 2 adrenergic agonist.
Since 2018, dexmedetomidine, an alpha 2 adrenergic agonist with sedative, analgesic and anxiolytic properties, is being used as a current and standard practice in our anesthesia department. Intravenous administrationis performed ten to twenty minutes before spinal anesthesia placement in all children weighing less than 7 kg undergoing an infra-umbilical surgery of expected duration of less than 1 hour. This strategy ensures the child's comfort and allows the procedure to be performed under optimal conditions for practitionner.
The objective of this study is to review our practices and to evaluate the impact of the use of dexmedetomidine during spinal anesthesia of newborns and infants.

Registry

clinicaltrials.gov

Start Date

October 1, 2020

End Date

November 28, 2023

Last Updated

5 years ago

Study Type

Observational

Sex

All